Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
The eczema treatment Nektar Therapeutics is developing helped a surprising percentage of patients achieve skin clearance. 10 stocks we like better than Nektar Therapeutics › Shares of Nektar Therapeutics (NASDAQ: NKTR) , a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence . Investors have been increasingly enthusiastic about recently announced clinical trial results for its lead candidate, rezpegaldesleukin. In a nutshell, it looks like it could become a top-selling treatment for eczema, an itchy autoimmune disorder that affects roughly 10% of American adults. Image source: Getty Images. Nektar's experimental eczema candidate could be a top performer Nektar Therapeutics was founded in 1990, but it doesn't have any commercial-stage drugs that generate revenue right now. For companies in this precarious position, any sign that an experimental candidate could have blockbuster potential can lead to huge gains. Rez
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- NKTR's page on the SEC website